Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | Alpelisib | 1 | 72 | 0.001 | 4167.0 | 4320.3 | 1295.5 | -3.0 | 0.959 | 0.965 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 0.0032 | 3784.0 | 4320.3 | 1295.5 | -2.49 | 0.853 | 0.876 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 0.01 | 4336.3 | 4320.3 | 1295.5 | -2.0 | 1.000 | 1.000 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 0.032 | 4291.8 | 4320.3 | 1295.5 | -1.49 | 0.992 | 0.993 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 0.1 | 4138.5 | 4320.3 | 1295.5 | -1.0 | 0.951 | 0.958 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 0.32 | 3978.5 | 4320.3 | 1295.5 | -0.495 | 0.907 | 0.921 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 1.0 | 3771.8 | 4320.3 | 1295.5 | 0.0 | 0.850 | 0.873 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | Alpelisib | 1 | 72 | 3.2 | 3448.8 | 4320.3 | 1295.5 | 0.505 | 0.757 | 0.798 | 1.738 | HCC38 BYL719 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.001 | 4239.0 | 4275.5 | 1295.5 | -3.0 | 0.990 | 0.991 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.0032 | 4366.5 | 4275.5 | 1295.5 | -2.49 | 1.020 | 1.020 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.01 | 4368.3 | 4275.5 | 1295.5 | -2.0 | 1.030 | 1.020 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.032 | 4361.3 | 4275.5 | 1295.5 | -1.49 | 1.020 | 1.020 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.1 | 4322.0 | 4275.5 | 1295.5 | -1.0 | 1.010 | 1.010 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 0.32 | 4185.0 | 4275.5 | 1295.5 | -0.495 | 0.975 | 0.979 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 1.0 | 4134.5 | 4275.5 | 1295.5 | 0.0 | 0.961 | 0.967 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | CAL-101 | 1 | 72 | 3.2 | 3986.8 | 4275.5 | 1295.5 | 0.505 | 0.920 | 0.932 | 1.723 | HCC38 CAL101 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.001 | 2986.0 | 4216.8 | 1295.5 | -3.0 | 0.633 | 0.708 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.0032 | 2843.5 | 4216.8 | 1295.5 | -2.49 | 0.587 | 0.674 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.01 | 2865.3 | 4216.8 | 1295.5 | -2.0 | 0.594 | 0.679 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.032 | 2788.5 | 4216.8 | 1295.5 | -1.49 | 0.569 | 0.661 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.1 | 2800.5 | 4216.8 | 1295.5 | -1.0 | 0.573 | 0.664 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 0.32 | 2752.8 | 4216.8 | 1295.5 | -0.495 | 0.557 | 0.653 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 1.0 | 2701.5 | 4216.8 | 1295.5 | 0.0 | 0.540 | 0.641 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Everolimus | 1 | 72 | 3.2 | 2708.5 | 4216.8 | 1295.5 | 0.505 | 0.542 | 0.642 | 1.703 | HCC38 Everolimus 0 1 72 |
| HCC38 | Pictilisib | 1 | 72 | 0.001 | 4454.8 | 4386.3 | 1295.5 | -3.0 | 1.020 | 1.020 | 1.759 | HCC38 GDC0941 0 1 72 |